Tag: Guselkumab
Promising phase 2 results for new plaque psoriasis therapy
1. Guselkumab, an anti-interleukin-23 antibody, produced better responses in patients with moderate to severe plaque psoriasis than standard anti-TNF alpha ...
1. Guselkumab, an anti-interleukin-23 antibody, produced better responses in patients with moderate to severe plaque psoriasis than standard anti-TNF alpha ...